Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoTSE:4519 -2.15%96 EV-to-FCF is 33.27 as of Jul. 14, 2026, which is 14% below its 10-year median of 38.55. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,735.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 562 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 63.35% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chugai Pharmaceutical Co's Enterprise Value is 円11,048,772 Mil.
Chugai Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円332,045 Mil. Therefore, Chugai Pharmaceutical Co's EV-to-FCF for today is 33.27.
The historical rank and industry rank for Chugai Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4519'
s EV-to-FCF Range Over the Past 10 Years
Min: 14.78 Med: 38.55 Max: 2782.11
Current: 34.06
During the past 13 years, the highest EV-to-FCF of Chugai Pharmaceutical Co was 2782.11. The lowest was 14.78. And the median was 38.55.
TSE:4519's EV-to-FCF is ranked worse than 63.35% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs TSE:4519: 34.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chugai Pharmaceutical Co (TSE:4519) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chugai Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Chugai Pharmaceutical Co's share price for today is 円7230.00.
Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円274.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chugai Pharmaceutical Co EV-to-FCF Related Terms
Chugai Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's EV-to-FCF falls into.
Chugai Pharmaceutical Co's current Enterprise Value is 円11,048,772 Mil.
Chugai Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円332,045 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (TSE:4519) has a EV-to-FCF of 33.27 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chugai Pharmaceutical Co and its competitors. This is 14% below median its historical median of 38.55. Over the past decade, Chugai Pharmaceutical Co's EV-to-FCF has ranged from 14.78 to 2,782.11. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #356 out of 562 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Chugai Pharmaceutical Co's EV-to-FCF too high?
Chugai Pharmaceutical Co's current EV-to-FCF of 33.27 is 14% below median its 10-year median of 38.55. Over the past 10 years, this metric has ranged from a low of 14.78 to a high of 2,782.11. The Drug Manufacturers industry median EV-to-FCF is 21.06. Chugai Pharmaceutical Co's value of 33.27 is 58% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #356 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #356 out of 562 companies for EV-to-FCF. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 21.06. Chugai Pharmaceutical Co's value of 33.27 is 58% above this benchmark. Historically, Chugai Pharmaceutical Co's own EV-to-FCF has ranged from 14.78 to 2,782.11 over the past decade. While the company's 10-year median is 38.55 vs. the industry median of 21.06, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current EV-to-FCF of 33.27 is 58% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current EV-to-FCF is 33.27, which is 14% below median its own 10-year median of 38.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,735.19, compared to a current price of 円7,230.00 — trading 6.5% below its estimated fair value. The current EV-to-FCF is 33.27, which is 14% below median its 10-year median of 38.55 and 58% above the Drug Manufacturers industry median of 21.06. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current EV-to-FCF is 33.27 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
EV-to-FCF: 33.27 (14% below median its 10-year median of 38.55)
GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
Industry Position: 58% above the Drug Manufacturers median (#356 of 562)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score
Get the complete analysis for TSE:4519
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
